These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 26522070)
1. Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis. Roblek M; Calin M; Schlesinger M; Stan D; Zeisig R; Simionescu M; Bendas G; Borsig L J Control Release; 2015 Dec; 220(Pt A):341-347. PubMed ID: 26522070 [TBL] [Abstract][Full Text] [Related]
2. VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes. Calin M; Stan D; Schlesinger M; Simion V; Deleanu M; Constantinescu CA; Gan AM; Pirvulescu MM; Butoi E; Manduteanu I; Bota M; Enachescu M; Borsig L; Bendas G; Simionescu M Eur J Pharm Biopharm; 2015 Jan; 89():18-29. PubMed ID: 25438248 [TBL] [Abstract][Full Text] [Related]
3. CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis. Roblek M; Protsyuk D; Becker PF; Stefanescu C; Gorzelanny C; Glaus Garzon JF; Knopfova L; Heikenwalder M; Luckow B; Schneider SW; Borsig L Mol Cancer Res; 2019 Mar; 17(3):783-793. PubMed ID: 30552233 [TBL] [Abstract][Full Text] [Related]
4. Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding. Roblek M; Strutzmann E; Zankl C; Adage T; Heikenwalder M; Atlic A; Weis R; Kungl A; Borsig L Neoplasia; 2016 Jan; 18(1):49-59. PubMed ID: 26806351 [TBL] [Abstract][Full Text] [Related]
6. Nano-Antagonist Alleviates Inflammation and Allows for MRI of Atherosclerosis. Mog B; Asase C; Chaplin A; Gao H; Rajagopalan S; Maiseyeu A Nanotheranostics; 2019; 3(4):342-355. PubMed ID: 31723548 [TBL] [Abstract][Full Text] [Related]
7. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628 [TBL] [Abstract][Full Text] [Related]
8. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521 [TBL] [Abstract][Full Text] [Related]
9. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Wolf MJ; Hoos A; Bauer J; Boettcher S; Knust M; Weber A; Simonavicius N; Schneider C; Lang M; Stürzl M; Croner RS; Konrad A; Manz MG; Moch H; Aguzzi A; van Loo G; Pasparakis M; Prinz M; Borsig L; Heikenwalder M Cancer Cell; 2012 Jul; 22(1):91-105. PubMed ID: 22789541 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of chemokine receptor CCR2 reduces sarcoma cell transendothelial migration and metastasis to the lungs. Schlesinger M; Zeisig R; Ortmann K; Calin M; Gerber U; Roblek M; Borsig L; Bendas G Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1046-8. PubMed ID: 26249764 [No Abstract] [Full Text] [Related]
12. The obesity and inflammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2). Maffei M; Funicello M; Vottari T; Gamucci O; Costa M; Lisi S; Viegi A; Ciampi O; Bardi G; Vitti P; Pinchera A; Santini F BMC Biol; 2009 Dec; 7():87. PubMed ID: 20017911 [TBL] [Abstract][Full Text] [Related]
13. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. Lu X; Kang Y J Biol Chem; 2009 Oct; 284(42):29087-96. PubMed ID: 19720836 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Radiation-Induced Ccl2 Signaling Protects Lungs from Vascular Dysfunction and Endothelial Cell Loss. Wiesemann A; Ketteler J; Slama A; Wirsdörfer F; Hager T; Röck K; Engel DR; Fischer JW; Aigner C; Jendrossek V; Klein D Antioxid Redox Signal; 2019 Jan; 30(2):213-231. PubMed ID: 29463096 [No Abstract] [Full Text] [Related]
16. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. An J; Xue Y; Long M; Zhang G; Zhang J; Su H Oncotarget; 2017 Jun; 8(24):39230-39240. PubMed ID: 28424406 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic insights into the role of the chemokine CCL2/CCR2 axis in dorsal root ganglia to peripheral inflammation and pain hypersensitivity. Dansereau MA; Midavaine É; Bégin-Lavallée V; Belkouch M; Beaudet N; Longpré JM; Mélik-Parsadaniantz S; Sarret P J Neuroinflammation; 2021 Mar; 18(1):79. PubMed ID: 33757529 [TBL] [Abstract][Full Text] [Related]
18. The CCL2/CCR2 axis enhances vascular cell adhesion molecule-1 expression in human synovial fibroblasts. Lin YM; Hsu CJ; Liao YY; Chou MC; Tang CH PLoS One; 2012; 7(11):e49999. PubMed ID: 23185512 [TBL] [Abstract][Full Text] [Related]
19. The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment. Regan DP; Coy JW; Chahal KK; Chow L; Kurihara JN; Guth AM; Kufareva I; Dow SW J Immunol; 2019 May; 202(10):3087-3102. PubMed ID: 30971441 [TBL] [Abstract][Full Text] [Related]